BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.04 USD | -0.35% |
|
+3.83% | +27.43% |
Financials (USD)
| Sales 2024 * | 38.81M | Sales 2025 * | 31.51M | Capitalization | 1.58B |
|---|---|---|---|---|---|
| Net income 2024 * | -192M | Net income 2025 * | -234M | EV / Sales 2024 * | 32.6 x |
| Net cash position 2024 * | 318M | Net cash position 2025 * | 254M | EV / Sales 2025 * | 42.2 x |
| P/E ratio 2024 * |
-5.15
x | P/E ratio 2025 * |
-4.5
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bicycle Therapeutics plc
More recommendations
More press releases
| 1 day | -0.35% | ||
| 1 week | +3.83% | ||
| Current month | +3.83% | ||
| 1 month | -2.29% | ||
| 3 months | -9.11% | ||
| 6 months | +45.92% | ||
| Current year | +27.43% |
1 week
22.21
23.56
1 month
20.9926.19
Current year
16.1327.24
1 year
12.5428.91
3 years
12.0862.08
5 years
6.2462.08
10 years
6.2462.08
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Lee
CEO | Chief Executive Officer | 55 | 15-08-31 |
Alethia Young
DFI | Director of Finance/CFO | 45 | 23-07-16 |
Alistair Milnes
COO | Chief Operating Officer | 50 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pierre Legault
CHM | Chairman | 63 | 19-03-17 |
| Director/Board Member | 61 | 21-03-16 | |
Richard Kender
BRD | Director/Board Member | 68 | 19-07-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 23.04 | -0.35% | 237,890 |
| 24-06-06 | 23.12 | -0.86% | 214,933 |
| 24-06-05 | 23.32 | +2.55% | 165,207 |
| 24-06-04 | 22.74 | -1.26% | 234,463 |
| 24-06-03 | 23.03 | +3.79% | 650,437 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
23.04
USD
Average target price
42.4
USD
Spread / Average Target
+84.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.43% | 1.58B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- BCYC Stock
